Highlights
- Second quarter net loss to common shareholders was about USD 720,000.
- Operating expenses were approximately USD 874,000 for the quarter.
- Cash and cash equivalents were about USD 7.9 million at June 30, 2026.
- The company reports no Debt and no preferred stock.
Vyome Holdings, Inc. (NASDAQ:HIND) shares were trading near their all-time low at USD 1.60 on November 6, 2026, down 2.15% on the day. The company reported a second quarter net loss attributable to common shareholders of approximately USD 720,000, or USD 0.10 per share.
Vyome is a clinical stage biopharmaceutical company focused on immuno inflammatory and rare disease conditions.
Quarter Results
Total operating expenses for the quarter ended June 30, 2026 were approximately USD 874,000, including approximately USD 507,000 in Research and Development expenses and approximately USD 365,000 in selling, general and administrative expenses. The net loss attributable to common shareholders was approximately USD 720,000, or approximately USD 0.10 per basic and diluted share.
Balance Sheet
Cash and cash equivalents were approximately USD 7.9 million at June 30, 2026 against approximately USD 5.0 million at December 31, 2025. Total current Assets were approximately USD 8.2 million, and total stockholders' Equity was approximately USD 7.3 million. Management describes a Capital Structure with no debt, no preferred stock and no toxic financing instruments.
VT-1953 Program
VT-1953 is a topical gel for malignant fungating wounds. Phase 2 data presented at the American Association for Cancer Research showed a statistically significant reduction in malodor, the primary endpoint, along with statistically significant improvements in the patient reported impact of malodor on daily life and in lesion pain, with no treatment emergent adverse events.
In March 2026 the company submitted a pre-IND briefing package to the FDA that included its proposed pivotal study strategy. It received the FDA's written response during the second quarter, is incorporating the feedback, and plans to continue engagement through a Type C meeting.
Pipeline and Patents
The company signed an agreement with Impetis Biosciences Limited to in-license two selective JAK inhibitor assets for potential use in autoimmune and inflammatory conditions. It also received a granted Chinese Patent covering formulation and therapeutic use claims related to its VB-1953 topical gel program for inflammatory acne.
Management Comment
Chairman Krishna Gupta said the company is taking a methodical and conservative approach to capital allocation. At USD 1.60 per share, Vyome has a market Capitalization of about USD 11.19 million.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...